
Cortex Pharmaceuticals, Inc. (NYSE Alternext US (COR)) reported that top-line data from its second Phase IIa study in opioid-induced respiratory depression (RD) demonstrated that a single oral dose of 1500mg of the AMPAKINEŽ compound CX717 achieved statistical significance (p = 0.
Click here for full Story http://www.medicalnewstoday.com/articles/124374.php |